nach oben

Drugs

Erschienen in:

01.09.2004 | Adis Drug Profile

Brivudin (Bromovinyl Deoxyuridine)

verfasst von: Susan J. Keam, Therese M. Chapman, David P. Figgitt

Erschienen in: Drugs | Ausgabe 18/2004

Einloggen, um Zugang zu erhalten

Abstract

▴ Brivudin is an oral thymidine analogue indicated for the early treatment of acute herpes zoster in immunocompetent adults. It has high, selective activity against varicella zoster virus (VZV), inhibiting VZV replication, possibly through competitive inhibition of viral DNA polymerase, or by acting as an alternative substrate to deoxythymidine triphosphate, causing viral DNA strand breakage.
▴ In a large, 7-day, phase III trial in immunocompetent patients with herpes zoster, once-daily brivudin 125mg was significantly more effective than oral acyclovir 800mg five times daily in reducing the mean time from start of treatment to last vesicular eruption, and was as effective as acyclovir at healing lesions and alleviating acute zoster-related pain.
▴ The likelihood of developing post-herpetic neuralgia (PHN) in immunocompetent patients aged ≥50 years was significantly lower with brivudin than with acyclovir.
▴ Brivudin was as effective as oral famciclovir 250mg three times daily in terms of the prevalence of PHN, the time to last vesicular eruption and lesion healing in another large, 7-day, phase III study in immunocompetent patients with herpes zoster.
▴ Oral brivudin is generally well tolerated, with a similar tolerability profile to those of oral acyclovir or famciclovir. Nausea was the most commonly reported adverse event.

Johnson RW. Herpes zoster and postherpetic neuralgia: optimal treatment. Drugs Aging 1997 Feb; 10(2): 80–94PubMedCrossRef

Wutzler P. Antiviral therapy of herpes simplex and varicellazoster virus infections. Intervirology 1997; 40(5–6): 343–56PubMedCrossRef

Whitley RJ, Shukla S, Crooks RJ. The identification of risk factors associated with persistent pain following herpes zoster. J Infect Dis 1998; 178 Suppl. 1: S71–75PubMedCrossRef

Wassilew SW, Wutzler P. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. On behalf of the Brivudin Herpes Zoster Study Group. Antiviral Res 2003 Jun; 59(1): 49–56PubMedCrossRef

Shigeta S, Yokota T, De Clercq E. Therapy of varicella-zoster virus infection: mechanism of action of (E)-5-(2-bromovinyl)-2′-deoxyuridine. Antiviral Res 1985; Suppl. 1: 35–44

Menarini International Operations Luxembourg S.A., Berlin-Chemie AG. Premovir® 125mg European SmPC. Menarini International Operations Luxembourg S.A. Berlin-Chemie AG, 2004

Andrei G, Snoeck R, Reymen D, et al. Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus. Eur J Clin Microbiol Infect Dis 1995 Apr; 14(4): 318–29PubMedCrossRef

Ono K, Nakane H, De Clercq E. Potent inhibitory effects of the 5′-triphosphates of (E)-5-(2-bromovinyl)-2′-deoxyuridine and (E)-5-(2-bromovinyl)-1-β-D-arabinofuranosyluracil on DNA polymerase γ. Eur J Biochem 1990 Jul 5; 190(3): 463–7PubMedCrossRef

Lilie HM, Wassilew SW. The role of antivirals in the management of neuropathic pain in the older patient with herpes zoster. Drugs Aging 2003; 20(8): 561–70PubMedCrossRef

10.

Shigeta S, Yokata T, Iwabuchi T, et al. Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus. J Infect Dis 1983; 147(3): 576–84PubMedCrossRef

11.

Baba M, Konno K, Shigeta S, et al. Inhibitory effects of selected antiviral compounds on newly isolated clinical varicella-zoster strains. Tohoku J Exp Med 1986; 148: 275–83PubMedCrossRef

12.

De Clercq E, Descamps J, Ogata M, et al. In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2′-deoxyuridine and related compounds. Antimicrob Agents Chemother 1982 Jan; 21(1): 33–8PubMedCrossRef

13.

Rabasseda X. Brivudine: a herpes virostatic with rapid antiviral activity and once-daily dosing. Drugs Today (Barc) 2003 May; 39(5): 359–71CrossRef

14.

Gross G, Doerr HW. Herpes zoster guidelines of the German Dermatological Society [letter]. J Clin Virol 2003; 27: 308–9PubMedCrossRef

15.

Keizer HJ, Cleton FJ, de Bruyn EA, et al. Pharmacokinetic and phase-1 studies of oral low dose bromovinyldeoxyuridine (BVdUrd) and 5-fluorouracil (FUra) infusion [abstract no. 132]. Invest New Drugs 1989 Nov; 7(4): 381

16.

Wassilew SW, Wutzler P. Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on postherpetic neuralgia. On behalf of the Brivudin Herpes Zoster Study Group. Antiviral Res 2003 Jun; 59(1): 57–60PubMedCrossRef

17.

Wutzler P, Wassilew S. Brivudin in the treatment of herpes zoster [abstract no. SA 183 plus poster]. 23rd International Congress of Chemotherapy; 2003 Jun 7–9; Durban, 23

18.

Wutzler P, De Clercq E, Wutke K, et al. Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomized double-blind trial. J Med Virol 1995 Jul; 46(3): 252–7PubMedCrossRef

Titel: Brivudin (Bromovinyl Deoxyuridine)
verfasst von: Susan J. Keam
Therese M. Chapman
David P. Figgitt
Publikationsdatum: 01.09.2004
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 18/2004
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200464180-00011

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 18/2004

Intravenous Lansoprazole

Emtricitabine/Tenofovir Disoproxil Fumarate

Antiviral Therapy for Influenza

Early-Stage Multiple Sclerosis

Intravenous Lansoprazole

Cabergoline